GlassScriptPhysician profile
Cameron J Wood
NPI 1003628413
$2,070.30
in general payments reported to CMS, 2019-2025
21 companies · $2,070 in 2025
The $2,070 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758 · Travel and Lodging: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.26 |
| Travel and Lodging | $312.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $478.97 | 2025 | Minimed 780g |
| Amgen INC. | $313.12 | 2025 | Evenity, Tepezza |
| Sanofi-Aventis U.S. LLC | $201.98 | 2025 | |
| Corcept Therapeutics | $169.41 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $141.18 | 2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $135.00 | 2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $104.15 | 2025 | |
| Beta Bionics, INC. | $94.78 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $70.87 | 2025 | Yorvipath |
| Radius Health, INC. | $67.22 | 2025 | Tymlos |
| Tandem Diabetes Care, INC. | $60.18 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $35.89 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.17 | 2025 | Jardiance |
| Dexcom, INC. | $32.81 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $32.04 | 2025 | Ozempic, Rybelsus |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.42 | 2025 | |
| Abbvie INC. | $16.37 | 2025 | |
| Ascensia Diabetes Care US INC. | $16.25 | 2025 | |
| Sequel Med Tech, LLC | $14.63 | 2025 | Twiist |
| Astellas Pharma US INC | $14.23 | 2025 | Veozah |
| Cequr Corporation | $9.63 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.